Maria Gluud

Maria Gluud

Auto-generated profile, based on publicly available information

Maria Gluud

LEO Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2018 in Blood Advances
Verified
Journal Article
Open access
PDF file
TBTerkild Brink Buus
Terkild Brink Buus
AWAndreas Willerslev-Olsen
Andreas Willerslev-Olsen
SFSimon Fredholm
Simon Fredholm
EBEdda Blümel
Edda Blümel
Claudia NastasiClaudia Nastasi
Claudia Nastasi
Niels OdumNiels Odum
Niels Odum
Key Points: Individual patients with Sézary syndrome contain several distinct malignant subpopulations and show marked single-cell heterogeneity. Malignant subpopulations exhibit differences in their sensitivity to treatment warranting precision therapy.

12 January 2023 in Blood
Verified
Journal Article
Open access
PDF file
MGMaria Gluud
Maria Gluud
EPEmil Marek Heymans Pallesen
Emil Marek Heymans Pallesen
TBTerkild Brink Buus
Terkild Brink Buus
Lise Mette Rahbek GjerdrumLise Mette Rahbek Gjerdrum
Lise Mette Rahbek Gjerdrum
LLLise M. Lindahl
Lise M. Lindahl
Niels OdumNiels Odum
Niels Odum
Cutaneous T-cell lymphoma (CTCL) is a devastating lymphoid malignancy characterized by the accumulation of malignant T cells in the dermis and epidermis. Skin lesions cause serious symptoms that hamper quality of life and are entry sites for bacterial infection, a major cause of morbidity and mortality in advanced diseases. The mechanism driving the pathological processes that compromise the skin barrier remains unknown. Here, we report increased transepidermal water loss and compromised expression of the skin barrier proteins filaggrin and filaggrin-2 in areas adjacent to TOX-positive T cells in CTCL skin lesions. Malignant T cells secrete mediators (including cytokines such as interleukin 13 [IL-13], IL-22, and oncostatin M) that activate STAT3 signaling and downregulate filaggrin and filaggrin-2 expression in human keratinocytes and reconstructed human epithelium. Consequently, the repression of filaggrins can be counteracted by a cocktail of antibodies targeting these cytokines/receptors, small interfering RNA–mediated knockdown of JAK1/STAT3, and JAK1 inhibitors. Notably, we show that treatment with a clinically approved JAK inhibitor, tofacitinib, increases filaggrin expression in lesional skin from patients with mycosis fungoides. Taken together, these findings indicate that malignant T cells secrete cytokines that induce skin barrier defects via a JAK1/STAT3-dependent mechanism. As clinical grade JAK inhibitors largely abrogate the negative effect of malignant T cells on skin barrier proteins, our findings suggest that such inhibitors provide novel treatment options for patients with CTCL with advanced disease and a compromised skin barrier.

18 June 2016 in Oncotarget
Verified
Journal Article
Open access
Lise M. LindahlLise M. Lindahl
Lise M. Lindahl
SFSimon Fredholm
Simon Fredholm
CJClaudine Joseph
Claudine Joseph
BNBoye Schnack Nielsen
Boye Schnack Nielsen
LJLars Jønson
Lars Jønson
Niels OdumNiels Odum
Niels Odum
STAT5 induces miR-21 expression in cutaneous T cell lymphoma

6 March 2023 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
EPEmil M.H. Pallesen
Emil M.H. Pallesen
MGMaria Gluud
Maria Gluud
CVChella Krishna Vadivel
Chella Krishna Vadivel
TBTerkild Brink Buus
Terkild Brink Buus
BRBob de Rooij
Bob de Rooij
Niels OdumNiels Odum
Niels Odum
Staphylococcus aureus is suspected to fuel disease activity in cutaneous T-cell lymphomas. In this study, we investigate the effect of a recombinant, antibacterial protein, endolysin (XZ.700), on S. aureus skin colonization and malignant T-cell activation. We show that endolysin strongly inhibits the proliferation of S. aureus isolated from cutaneous T-cell lymphoma skin and significantly decreases S. aureus bacterial cell counts in a dose-dependent manner. Likewise, ex vivo colonization of both healthy and lesional skin by S. aureus is profoundly inhibited by endolysin. Moreover, endolysin inhibits the patient-derived S. aureus induction of IFNγ and the IFNγ-inducible chemokine CXCL10 in healthy skin. Whereas patient-derived S. aureus stimulates activation and proliferation of malignant T cells in vitro through an indirect mechanism involving nonmalignant T cells, endolysin strongly inhibits the effects of S. aureus on activation (reduced CD25 and signal transducer and activator of transcription 5 phosphorylation) and proliferation (reduced Ki-67) of malignant T cells and cell lines in the presence of nonmalignant T cells. Taken together, we provide evidence that endolysin XZ.700 inhibits skin colonization, chemokine expression, and proliferation of pathogenic S. aureus and blocks their potential tumor-promoting effects on malignant T cells.

1 August 2018 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
SFSimon Fredholm
Simon Fredholm
AWAndreas Willerslev-Olsen
Andreas Willerslev-Olsen
ÖMÖzcan Met
Özcan Met
LKLinda Kubat
Linda Kubat
MGMaria Gluud
Maria Gluud
Niels OdumNiels Odum
Niels Odum

17 July 2019 in OncoImmunology
Verified
Journal Article
Open access
EBEdda Blümel
Edda Blümel
AWAndreas Willerslev-Olsen
Andreas Willerslev-Olsen
MGMaria Gluud
Maria Gluud
Lise M. LindahlLise M. Lindahl
Lise M. Lindahl
SFSimon Fredholm
Simon Fredholm
Niels OdumNiels Odum
Niels Odum
Staphylococcus aureus is implicated in disease progression in cutaneous T-cell lymphoma (CTCL). Here, we demonstrate that malignant T cell lines derived from CTCL patients as well as primary malignant CD4+ T cells from Sézary syndrome patients are considerably more resistant to alpha-toxin-induced cell death than their non-malignant counterparts. Thus, in a subset of Sézary syndrome patients the ratio between malignant and non-malignant CD4+ T cells increases significantly following exposure to alpha-toxin. Whereas toxin-induced cell death is ADAM10 dependent in healthy CD4+ T cells, resistance to alpha-toxin in malignant T cells involves both downregulation of ADAM10 as well as other resistance mechanisms. In conclusion, we provide first evidence that Staphylococcus aureus derived alpha-toxin can tilt the balance between malignant and non-malignant CD4+ T cells in CTCL patients. Consequently, alpha-toxin may promote disease progression through positive selection of malignant CD4+ T cells, identifying alpha-toxin as a putative drug target in CTCL.